Meijin Huang

Title: Meijin Huang: Innovator in Colorectal Cancer Treatment

Introduction

Meijin Huang is a notable inventor based in Guangdong, China. She has made significant contributions to the field of oncology, particularly in the treatment of colorectal cancer. Her innovative work has led to the development of a pharmaceutical composition that shows promise in treating locally advanced mismatch repair-proficient/microsatellite stable (pMMR/MSS) colorectal cancer.

Latest Patents

Meijin Huang holds a patent for a pharmaceutical composition aimed at treating locally advanced pMMR/MSS colorectal cancer. The patent details a combination of mFOLFOX6, bevacizumab, and a PD-1 inhibitor. Experimental results indicate that this composition has achieved major pathological remission in 14 out of 18 cases, with a complete pathological response in 10 cases. The treatment has demonstrated a significant reduction in tumor marker levels and has been noted for its safety and efficacy, with no fatal serious adverse events reported.

Career Highlights

Meijin Huang is affiliated with The Sixth Affiliated Hospital, Sun Yat-Sen University, where she conducts her research and clinical work. Her dedication to improving cancer treatment has positioned her as a key figure in the medical community.

Collaborations

Meijin Huang collaborates with esteemed colleagues, including Yanhong Deng and Jianping Wang, who contribute to her research efforts and advancements in cancer treatment.

Conclusion

Meijin Huang's innovative work in developing a pharmaceutical composition for colorectal cancer treatment highlights her commitment to advancing medical science. Her contributions are paving the way for more effective cancer therapies and improving patient outcomes.